[1] Hui KF, Ho DN, Tsang CM, et al. Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma[J]. Int J Cancer, 2012, 131(8):1930 - 1940.
[2] Lifang Y, Min T, Midan A, et al. HSV-tk / GCV gene therapy mediated by EBV-LMP1 for EBV-associated
cancer[J]. J Exp Clin Cancer Res, 2008,23 - 27:42.
[3] He Y, Cai S, Zhang G, et al. Interfering with cellular signaling pathways enhances sensitization to combined sodium butyrate and GCV treatment in EBV positive tumor cells[J]. Virus Res, 2008,135(1):175 - 180.
[4] Seo JS, Cho NY, Kim HR, et al. Cell cycle arrest and lytic induction of EBV-transformed B lymphoblastoid cells by a histone deacetylase inhibitor, Trichostatin A[ J].
Oncol Rep, 2008, 19(1):93 - 98.
[5] Masanori D, Eva-Maria E, James E, et al. Antisense oligodeoxynucleotides against the BZLF1 transcript inhibit induction of productive Epstein-Barr virus replication[J]. Antiviral Research, 1996, 29:243 - 260.

[6] Tao Q, Chan AT. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments [ J]. Expert Rev Mol, 2007, 9(12):1 - 24.
[7] Gill MB, Kutok JL, Fingeroth JD. Epstein Barr virus thymidine kinase is a centrosomal resident precisely localized to the periphery of centrioles[ J]. J Virol,2007,81(12):6523 - 6535.